SERA - NASDAQ
Sera Prognostics, Inc.
$2.25
+9.5%Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
At a Glance
Live Snapshotsera
Total Non-Current Assets
Last Annual Value
61.16M
3-Year CAGR
33%
5-Year CAGR
125%
10-Year CAGR
43%
Sera Prognostics, Inc. Competitors Analysis of Total Non-Current Assets
| Company | Total Non-Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Sera Prognostics, Inc. NASDAQ:SERA | 61.16M | 21.5% | 10.7% | N/A | |
 Rapid Micro Biosystems, Inc. NASDAQ:RPID | 13.68M | -15.9% | -9.9% | N/A | |
 Apyx Medical Corporation NASDAQ:APYX | 8.37M | -1.9% | 0.9% | -0.2% | |
 Context Therapeutics Inc. NASDAQ:CNTX | 140.07K | 108.2% | 22.7% | N/A | |
 DocGo Inc. NASDAQ:DCGO | 64.70M | -24.7% | 3.8% | N/A | |
 Ovid Therapeutics Inc. NASDAQ:OVID | 60.49M | 20.7% | 71.6% | 58.2% | |
 Insight Molecular Diagnostics Inc. NASDAQ:IMDX | 10.45M | -45.4% | -38.7% | 19.6% | |
 VistaGen Therapeutics, Inc. NASDAQ:VTGN | 2.27M | -14.2% | -11.5% | 32.6% | |
 Armata Pharmaceuticals, Inc. AMEX:ARMP | 66.21M | -5.8% | 3.9% | 18.8% | |
 Lucid Diagnostics Inc. NASDAQ:LUCD | 2.98M | -16.9% | 11.9% | N/A | |
 TuHURA Biosciences, Inc. NASDAQ:HURA | 22.73M | 382.0% | 99.4% | 88.4% |
Sera Prognostics, Inc. Fair Value Envelope
Related Guides
Continue your SERA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.